Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04427429 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| PF-04427429 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | Normal saline |
| Name | Type | Description |
|---|---|---|
| PF-04427429 | BIOLOGICAL | Intravenous, single dose given over 1 hour with experimental dose. Subjects can receive one of four potential doses - 300, 1000, 1500 or 2000 mg. |
| Normal saline | OTHER | Intravenous, normal saline |
Inclusion Criteria: * Generally healthy women, of non-child bearing potential, between the ages of 18 and 65 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate meas...
PF-04427429 is an investigational monoclonal antibody developed by Pfizer for pain, including migraine disorders. It has been studied in a Phase 1 clinical trial in healthy women volunteers. It is not approved and remains in clinical development.
PF-04427429 is being studied for the treatment of pain, with trial conditions including migraine disorders. The research is at an early stage, and the drug has not been approved for any use.
PF-04427429 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer conducted the Phase 1 study of the drug in the United States.
PF-04427429 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are ongoing. The drug is investigational and has not been approved by the FDA.
PF-04427429 has been evaluated in one completed Phase 1 trial, NCT01511497, titled a study of safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy women volunteers. The trial enrolled 31 participants in the United States and was randomized, double-blind, and placebo-controlled.